TW425285B - Fish oil and garlic nutritive supplement - Google Patents
Fish oil and garlic nutritive supplement Download PDFInfo
- Publication number
- TW425285B TW425285B TW085111211A TW85111211A TW425285B TW 425285 B TW425285 B TW 425285B TW 085111211 A TW085111211 A TW 085111211A TW 85111211 A TW85111211 A TW 85111211A TW 425285 B TW425285 B TW 425285B
- Authority
- TW
- Taiwan
- Prior art keywords
- item
- nutritional composition
- patent application
- fish oil
- garlic
- Prior art date
Links
- 235000004611 garlic Nutrition 0.000 title claims abstract description 31
- 235000021323 fish oil Nutrition 0.000 title claims description 53
- 244000245420 ail Species 0.000 title abstract 2
- 230000000050 nutritive effect Effects 0.000 title 1
- 239000013589 supplement Substances 0.000 title 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims abstract description 86
- 229960002504 capsaicin Drugs 0.000 claims abstract description 43
- 235000017663 capsaicin Nutrition 0.000 claims abstract description 43
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 26
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 25
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 25
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000005493 rutin Nutrition 0.000 claims abstract description 25
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 25
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960004555 rutoside Drugs 0.000 claims abstract description 25
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 61
- 240000002234 Allium sativum Species 0.000 claims description 29
- 235000016709 nutrition Nutrition 0.000 claims description 29
- 229940029982 garlic powder Drugs 0.000 claims description 16
- -1 aromatic glycoside Chemical class 0.000 claims description 13
- 230000002079 cooperative effect Effects 0.000 claims description 9
- 229930182470 glycoside Natural products 0.000 claims description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 241000258920 Chilopoda Species 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 14
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 14
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 6
- 210000002381 plasma Anatomy 0.000 abstract description 5
- 235000019198 oils Nutrition 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract 3
- 235000006486 human diet Nutrition 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 32
- 108010007622 LDL Lipoproteins Proteins 0.000 description 14
- 102000007330 LDL Lipoproteins Human genes 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 12
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007937 lozenge Substances 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 240000009164 Petroselinum crispum Species 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 235000011197 perejil Nutrition 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940093797 bioflavonoids Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 244000044849 Crotalaria juncea Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 235000003976 Ruta Nutrition 0.000 description 1
- 240000005746 Ruta graveolens Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000005806 ruta Nutrition 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940053939 vanillylamine Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Description
經濟部中央標準局貝工消费合作社"製 4252 85 a? __B7_五、發明説明(1 ) 1 ·發明領域 本發明爲預防人類系統中之心臟血管性疾病提供新的 混合物•更清楚地說此營養混成物含魚油、蒜、芸香苷及 辣椒素此可降低人類血清中之甘油三酯、膽固醇及低密度-脂蛋白(LDL)濃度且增加高密度脂蛋白(HDL)之 濃度。 2 .發明背景 在過去數年中科學性文章提供強有力的證據顯示微量 營養混合物(例如維生素、礦物質、魚油及植物萃取物) 與心臟血管性疾病之相關性*已知對得心臟血管性疾病高 危險群之人而言* 了解相當程度地降低他們血清中之髙濃 度膽固醇、甘油三酯及低密度脂蛋白對降低得心臟病之危 險是非常重要的。亦知增加高密度脂蛋白濃度可顯著地降 低得心臟病之危險。 心臟血管性疾病起因於小動脈栓之堆稹,此病已知爲 導致人類病重死亡之主因。小動脈栓是因沈澱性物質之形 成,主要爲氧化低密度脂蛋白(0 — LDL) •栓以0 — L D L形式堆積於動脈中已知是缺血性心臟病的一個因素 。自由基氧化劑可將LDL氧化成具破壞性形式之0-L D L。許多此類氧化劑是源於天然發生的例如於陽光曝 曬、某些養分的代謝、運動或常見於糖尿病及高血壓之患 者。自由基之"清除劑#如維他命A、Ε,C及砷被認爲 可與此氧化劑反應使其無法氧化*這些抗氧化劑之抑制作 本紙張尺度適用中國國家揉隼(CNS ) A4規格(2iOX297公釐) (請先閲讀背面之注意事項寫本頁) -4 - A7 B7 經濟部中央搮準局員工消費合作社印袈 —^· '」“·.岸‘五、發明説明(2 ) 用因而抑止〇 — LDL之形成,且降低小動脈栓於血管中 積存之濃度。相反地,存在於體內之高密度脂蛋白( HDL)已知對健康有益·特別是HDL已知是較爲可溶 性的脂蛋白因此它的存在並未明顯地參與小動脈栓之形成— 。另外已知H D L可以吸收栓之物質而可能直接地降低小 動脈栓之量。 3 .先前抟蕕之詳沭 必要脂肪酸(E F A s )是天然產生之未飽合脂肪酸 具鍵長1 8、20或22個碳原子》這些£卩厶3無#由 體內合成因此必需由飲食中攝取•兩種屬於E F A s族之 脂肪酸爲廿碳五烯酸(E PA)及廿二碳六烯酸(DHA )此二者均常見於魚油•流行病學之觀察顯示魚油可降低 血小板之凝聚及血清甘油三酯因而可降低得心肌梗塞、高 血壓、動脈粥樣硬化及某些癌症之危險性〔Gerster, H., Internat, J. Vit. Nutr, Res., 6 5 : 3 — 2 0 ( 1994)〕。特別是已知源由魚油之EPA與DHA在 多數細胞膜扮演著重要的結構性角色,且影響細胞膜之流 動性。此特性藉著降低全血液之黏稠度和增加紅血球之彎 曲度及變形性而表現出來〔Gerster,同上引述〕。再者, E FA s如E PA及DHA是類甘烷一類物質之前驅物,' 此類化合物包括類前列腺素烷類如前列腺素、前列凝素、 白三烯素及氫氧基脂肪酸•類甘烷類已知影響血小板聚集 、穿透性及血管壁之正常狀態、血壓及發炎性免疫反應〔 本紙張尺度適用中國國家棣準(CNS ) A4^格(210X297公釐) ' (請先閲讀背面之注意事項κ ι寫本頁) .袭· 訂 線 經濟部中央橾隼局員工消費合作社印聚 4252 8b a? __B7_五、發明説明(3 ) Gerster,同上引述〕β 於飲食上添加魚油已知尙有其它有益健康之效果。肝 糖儲存之疾病是一種遺傳疾病,且常因嚴重的血脂蛋白過胃 高及萵膽固醇血使病情更複雜,彼增加早熟性粥樣硬化及-心臟血管性疾病之危險。已知有肝糖儲存病之病人若接受 10克之魚油經3個月後可顯著地降低血清中之甘油三酯 濃度( — 49%)及膽固醇濃度(一 23%) 、LDL濃 度(一 40%)且顯著增加血清中HDL之濃度( + 30 % ) C Levy, E. e t al.,I. Am. J. Clin. N n t. r. . 57 :922-29 (1993)〕。 蒜粉已被認爲有數項有益人體之處如預防心臟血管性 疾病。比如說每日吃蒜以降低血清中脂質濃度增進血織維 蛋白溶酶作用及組織血嫌維蛋白溶酶原活化因子(t — P A )之活性且可降低血漿血級維蛋白原之黏度,上述各 項均可降低發生心臟血管性疾病之可能〔Brosche,T. et a 1 _,British J. Clin. Prae t i ce . Sunn. 6 9 : 2 4 — 29 (1990)〕*再者日食大蒜已知可降低人類血清 之膽固醇及甘油三酯之總濃度同時亦降低血壓及週邊血管 擴張〔Auer, W. e t a 1. , British J . Clin. Practice. Sudd. 6 9:3 — 6 (1990)〕* 類黃酮是次級代謝物彼存於可食性植物及植物性食品 •類黃酮被廣泛地認爲具抗過敏性、抗發炎性、抗病毒性 、抗增殖性及抗致癌性〔Manach,C., et al. J . N u t r.. 1 2 5-1 911 — 22 (1995) 〕·在類黃酮中黃 -----------^------ΐτ------0 ί - - - (請先閱讀背面之注意事項孑丨寫本頁) 本紙浪尺度適用中國國家棣率(CNS > A4規格(210X297公釐} 經濟部中央標準局貝工消費合作社印策 4252 85 a? _________B7_ 五、發明説明(4 ) 酮醇在植物中最豐富且具上述諸生物特性〔Manach ,如上 引述〕。黃酮醇天然產爲〇—糖苷*通常在碳三位置上有 糖部分相結合。芸香苷是主要糖苷形式之解皮酮,亦是水 果及蔬菜中最豐富的黃酮醇。 辣椒素是辣椒屬植物最顯著地化學物質,此屬包括了 智利辣椒、紅辣椒及紅椒。辣椒素其實是一類具支鏈或直 鏈之烷基香草基醯胺。辣椒素之抗微生物及麻醉性已知達 數世紀了•再者含辣椒素之產品已被用於治療類風濕性關 節炎、骨關節炎、糖尿病性神經病、泡疹後(postherpetic) 神經痛 、乳房切除後疼痛症 、群集的頭痛及反射交 感症〔Cordell, G, and Araujo, 0.,Ann Pharm. , 2 7 :330-336(1993)〕 雖然用未降低得心臟血管性疾病之組成物已存在,但 本發明之組合含新的組成由魚油、蒜、芸香苷及辣椒素以 達上述效果。另外在此技藝中亦有需要有新的組成物如本 發明彼可用於治療及防範心臟血管性疾病或不適。 發明概述 本發明是關於用營養組成物以克服營養上之缺乏,主 要用於一般西方人的肷食。本發明之組成物於混合魚油、 蒜粉、芸香Μ及辣椒素而得*更明確地說本發明有關每曰 共同服用一製劑之魚油,較佳爲單一魚油錠劑及一製劑包 括蒜粉、芸香苷及辣椒素較隹爲此乃單一錠劑。 因此本發明之目標是供給人類既營養又安全之飮食組 本紙張尺度適用中國國家梯準(CNS ) Α4規格(210 X 297公釐) ----------裝------訂------^—1 . > - ' (請先閲讀背面之注$項f \寫本頁) 425285 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(5 ) 成物彼包括魚油、蒜粉、芸香苷及辣椒素· 另一目標是提供新的組成物彼可增加人類血清中之 H D L濃度· 更希望本發明得以提供組成物彼可降低人類血清中之 ◦一LDL之濃度。 本發明之另一目標爲降低人類血清中之膽固醇及甘油 三酯之濃度· 增加H D L及降低膽固醇及0- L D L將可降低人類 得心臟病之危機。因此本發明之另一目檫是藉著每日服用 本發明之組成物提供降低心臟血管性疾病之危機* 詳細說明本發明 本發明組成物之日劑量目標在降低心臓病之發生率且 包括(1)魚油(2)蒜粉(3)芸香苷及(4)辣椒素 。更明確地說本發明之組成物是結合了魚油製劑,最好是 單一魚油錠劑,及包括蒜粉、芸香苷及辣椒素之製劑,最 好是單一錠劑彼可與魚油錠同服用*魚油錠之較佳重量是 在5 0 0毫克至大約1 5 0 0毫克間,最好是大約 1000毫克。大蒜錠之較佳重爲約400毫克至約 1000毫克,最好是大約700毫克* 本發明魚油製劑之成份可取於商業來源〔Arista,' Pharmachem〕·ΕΡΑ與DHA是魚油製劑中具活性之部 分•本發明之魚油製劑包括Ε ΡΑ約在2 5 0毫克至 3 5 0毫克•最佳爲大約3 0 0毫克•其餘之魚油製備包 本紙張尺度適用中國國家標準(CNS )八4規格(210 X 297公釐> (請先閱讀背面之注意事項寫本頁) 經濟部中央標準局貝工消費合作社印11 五、發明説明(6 ) 括約150毫克至250毫克之DHA,最佳爲約200 毫克•本發明魚油製備之總重是大約5 0 0毫克至 1 5 0 0毫克,較佳爲大約1 0 0 0毫克每魚油錠當彼爲 單一形式之魚油錠。 用於本發明組成物之大蒜粉亦可得自於商業產品〔 E X t r a c t s, A s h 1 a n d, P u r e - G a r〕。另外較宜用除臭及 熟化形式之蒜粉。製藥上可被接受之蒜粉形式而用於本發 明之組成物中,依重量大約在1 0 0至7 0 0毫克,而較 佳爲在大約1 7 5至6 5 0毫克,最好是每一個蒜/芳香 苷/辣椒素錠含5 0 0毫克之去臭熟化之蒜粉,當用於單 一淀時· 芸香苷用於本發明組成物之蒜、芳香苷、辣椒素製劑 時亦可由商業來源取得〔Westco Chemical, Freeman Industries, Inc.〕*芸香替部分於蒜粉、芸香替及辣椒 素製劑中,依重量約爲1 0至1 5 0毫克而最好是大約 1 0 0毫克。 辣椒素用於本發明之組成物亦可得自於商業產品〔 A 1 1 c h e m,G ο 〇 d Η o p e B 〇 t a n i c a 1 s〕。當應用本發明之蒜 粉、芳香苷及辣椒素製劑時,辣椒素部分依本發明組成物 佔重約2 0到1 5 0毫克,且最好含大約1 0 0毫克之辣 椒素· , 蒜粉、芸香苷及辣椒素諸部分均混合於同一製劑。此 製劑與魚油製劑同時服用一此二製劑構成本發明之組成。 此製劑可以通用之法製造。欲製備本發明之組成物上述魚 本紙張尺度適用ΐ國國家標準(CNS ) A4規格(210 X 297公釐) -----------^------1Τ------^ - ' - . . (請先閱讀背面之注意事項^‘_.舄本頁) -9 - 經濟部中央標準局員工消費合作社印製 ____B7_五、發明説明(7 ) 油及蒜/芸香苷/辣椒素製劑可當有效成份相混合並配以 合適之載體完全照通用的調合技術。此載體有極廣泛之形 式取決於欲服用之方式比如:口服、舌下,鼻服或胃腸外 服。 在準備口服式組成物時,任何通用之製藥介質均可用 。對口服液製備(如:懸浮液、酊液、溶液)介質包括如 下:水、油 '酒精、芳香劑、防腐劑、色素或相類均可採 用•載體如澱粉、糖、稀釋劑、顆粒劑、潤滑劑、結合劑 、分散劑或相似物均可用於準備口服固體(如:粉、膠囊 、丸、片、錠)。錠是較佳之口服形式*控制釋放形亦可 採用*因爲易於服用錠、片、丸及膠嚢代表較優勢之口服 形式因此固形薬劑載髖必需使用•若需要片劑可以用標準 技術糖衣或腸衣》 對於多加的非活性部分之例子彼可提供較易口服包括 但非偈限於樓檬生物類黃酮〔Botanical International, Freeman〕,荷蘭芹粉、維生素E、蜂臘、卵磷脂、明膠 '純化水及甘油。這些化合物可用於產生新的營養組成物 之錠。 胃腸外用產品其載體將包括無菌水,但其它成分亦可 加入例如爲加速溶解成爲保存之目的•注射懸浮液亦可準 備適當之液體載體懸浮劑或相類似之物可採用* ' 採本發明較佳之方法是使用者吞食•每日大約4到8 錠魚油劑,最好是服6錠並同時服用大約3到5錠蒜粉、 辣椒素及芸香Μ劑,最好是服4錠。 本紙張尺度適用中國國家標準( CNS ) Α4現格(210X2^7公釐) ~ -10 - ----------^------^------0 - - · * - - » (請先鬩讀背面之注f項f.烏本頁) 425285 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(8 ) 下列例子說明本發明之較佳實施例。這些例子只是用 來說明用而非欲侷限本發明於此形式。 實例一 本發明對人類脂質輪廓之影響被測定了。一項雙盲研 究在加州大學耳變醫學院進行,顯示出正確使用本發明提 供對人血清有如下之影響:(1 )顯著地降低甘油三酯濃 度;(2)顯著地降低膽固醇和LDL且(3)顯著地增 高H D L濃度。 在觀察期照下列議定書進行。十個人參加長達一個月 之研究每人每天吞下1 0錠》對照組於一個月中每天服用 10錠不具活性之安慰劑而實驗組相對地服用10錠本發 明製劑。每人服用3錠魚油及2錠蒜粉/芸香苷/辣椒素 (一日兩次)以達每日吞食+錠。錠劑之識別性不被服用 人或檢驗者所知(故稱雙隹盲研究)。在實驗開始時大約 4奄升之血清先收集,侍服用一個月後再收集一次。飢餓 狀態之脂質輪廓取由血漿樣品用脂質自動化分餾控制盤分 析〔Hewlett- Packard Co.〕*再者,電解質(包括耗離 子)及葡萄糖濃度是以Chera 1 8自動系統〔Hewlett-Packard Co.〕分析。此結果經統計分析法比較而示於附 S — ° ' 這些結果證實血漿中甘油三酯濃度較服安慰劑組降低 341%。再者,膽固醇濃度下降9%、LDL下降7% 。而HDL濃度上升17%。 氏張尺度適用中國國家梯準( CNS ) A4規格(210X297公釐) I丨t ! * 裝 奸 :-----線—---ΓΜ. (請先閱讀背面之注意事項再ΐ寫本頁) -11 - 4252 85 A7 B7 五、發明説明(9 ) 這些數據提供評估本發明對增加人類血清之HD L濃 度及降低膽固醇、甘油三酯及低密度脂蛋白(LDL)之 基礎* 實例二 下列提供本發明之較佳組成物。組成物以二種獨立製 劑供應:A錠(魚油)及B錠(蒜、辣椒素及芳香苷)。 合宜日服劑量爲6顆A錠及4顆B錠(另言之,3顆A錠 加2顆B錠每日服兩次以達日服10顆)· 成份 (請先閲讀背面之注意事項f寫本頁) A錠 B錠 經濟部中央標準局員工消費合作社印製 魚油 蒜粉 辣椒素 芸香苷 檸檬生物類黃酮 荷蘭芹粉 重量(毫克) 10 0 0 10 0 0 7 0 0 4 8 7 5 3 2 7 2 3 110 實例三 下列提供本發明之較佳組成物。組成物以二種獨立製 劑供應:A錠(魚油)及B錠(蒜、辣椒及芸香替)。合 本紙浪尺度適用中國國家標準(CNS ) A4規格(2ΙΟΧ2ΪΙ7公釐) 12 - 經濟部中央標準局員工消費合作社印农 4 Z5 2 8 b a? B7五、發明説明(10 ) 宜日服劑量爲6顆A錠及4顆B錠(另言之,3顆A錠加 2顆B錠每日服兩次以達日服10顆)。 成份 重量(毫克) Α錠 9 5 0 魚 油 B錠 7 0 0 =as m 粉 6 0 0 辣 椒素 5 0 芸 香甘 5 0 實例四 下例提供本發明之較佳組成物。組成物以單一製劑提 供。合宜劑量爲一次服五顆每日兩次。 成份 魚油=* 蒜粉 芳香苷 辣椒素 檸檬生 荷蘭芹 重量(毫克) 5 7 0 19 4 1 1 2 1 物類黃酮 11 粉 3 8 本紙悵尺度適用中國國家標準(CNS ) Α4说格(210X2^7公釐) -----------袭------ΪΤ------0 - - - - (請先閱讀背面之注意事項具ί,寫本頁) -13 - -p件一a:第85111211號專利申請案中文哪書修正頁η__民國,料 五、發明說明(卩 維生命Ε蜂蠘 卵磷脂 明膠 純化水 甘油 5 7 5 7 5 2 5 5 10 17 0 *魚油以300 _· 200之EPA:DHA構成 對本發明可有各樣修飾或變數均包含於上述諸說明對 熟於此技藝之人應是顯而易見地。本發明亦欲含蓋組成物 之修飾及變數及使用彼之方法以達成其專利使用得落入附 帶專利範圍或相當性之範圍內。 請 先 讀 背 面 之 注 項 t I裝 頁 訂 經濟部智慧財產局員工消費合作社印製 圖式簡要說明 附圖1 顯示魚油/大蒜的組合對脂質輪廓之影響,其係 以血漿樣品進行測試。其中分別檩明膽固醇( Choi )、甘油三酯(Trigl )、低密度脂蛋白( LDL )及高密度脂蛋白(HDL )之改變量,以相對 於安慰劑之對照組所改變的百分比(%)表示· 本紙張尺度適用中國@家標準(CNS)A4規格(210 X 297公釐) 線 -14 -
Claims (1)
- 425285Λ8 B8 C8 D8 年 條正 六、申請專利範圍 附件一 :第8 5 1 1 1 2 1 1號專利申請案 中文申請專利範圍修正本 民國8 9年10月修正 1 .—種營養組成物,其包括2 0 0至1 2 0 0份之 魚油、30至350份之蒜、3至75份之芸香替及6至 7 5份之辣椒素。 2. 如申請專利範圍第1項之營養組成物,其中該魚 油是單一魚油錠形式。 3. 如申請專利範圍第2項之營養組成物,其中該蒜 、芸香苷及辣椒素是單-蒜、芸香苷及辣椒素錠形式。 4. 如申請專利範圍第1項之營養組成物,其中該魚 油、蒜、芸香苷及辣椒素是單一錠形式。 5 '如申請專利範圍第3項之營養組成物,其中該魚 油錠是介於3 5 0毫克至6 5 0毫克。 6.如申請專利範圍第5項之營養組成物,其中該魚 油錠是5 0 0毫克》 7 .如申請專利範圍第3項之營養組成物,其中該蒜 是介於200毫克至7〇〇毫克、芸香苷是介於]_ 〇毫克 至150毫克且辣椒素是介於20毫克至150毫克》 8. 如申請專利範圍第7項之營養組成物,其中該魚 油是5 0 0毫克、蒜是5 〇 〇毫克、芸香苷是1 〇 〇毫克 且辣椒素是10¾毫克。 9. 如申請專利範圍第7項之營養組成物,其中該魚 油是500¾克、蒜是275毫克、芳香替是1 35¾克 衣紙ft乂度適用令國國家標隼(CNS ) Λ4現格(210X297公ΛΠ 1 — . 1 訂 —線 - * (請先閲讀背面之注意事項再填寫本買) 經凊部智兑^次^:只工:^^合作社印於 4252 85 as D8 六、申請專利範圍 且辣椒素是9 0毫克。 1 0 .如申請專利範圍第7項之營養組成物,其中該 魚油是6 0 〇毫克、蒜是2 0 0毫克、芳香苷是1 0毫克 且辣椒素是2 0毫克。 1 1 .如申請專利範圍第3項之營養組成物I其中該 蒜、芸香苷及辣椒素錠是介於3 5 0毫克至6 5 0毫克。 1 2 .如申請專利範圍第7項之營養組成物,其中該 蒜、芸香苷及辣椒素錠是5 0 0毫克》 1 3 .如申請專利範圍第3項之營養組成物,其中該 魚油錠及蒜、芳香苷及辣椒素錠之總重量是介於7 0 0毫 克至1 3 0 0毫克。 1 4 .如申請專利範圍第1 3項之營養組成物,其中 該魚油錠及蒜、芸香μ及辣椒素錠之總重量是1 0 0 〇毫 克。 15.如申請專利範圍第1項之營養組成物,其中該 魚油含介於250IU至350IU之ΕΡΑ。 1 6 .如申請專利範圍第1 5項之營養組成物,其中 該魚油含300IU ΕΡΑ。 1 7 .如申請專利範圍第1項之營養組成物,其中該 魚油含介於1 50 I U至250〗U之DHA。 1 8 .如申請專利範圍第1 7項之營養組成物,其中 該魚油含200IU DHA。 1 9 .如申請專利範圍第1項之營養組成物,其中該 蒜是蒜粉形式。 ----------1------ΪΤ-------,ii - · - {請先閱讀背面之注意事項再填寫本頁) 本紙张尺度通用中國國家標嗥(CNS ) 釐勹2 - 4252 85 ?s D8 六、申請專利範圍 20.—種製備如申請專利範圍第1項之營養組成物 之方法,其包括摻和魚油、蒜,芳香苷及辣椒素等成份於 適當之載體。 ' 2 1 .如申請專利範圍第3或4項之營養組成物,其-是用於每日增加人類血漿中HD L濃度。 2 2 .如申請專利範圍第3或4項之營養組成物,其 是用於每日降低人類血漿中0 — LDL、膽固醇及甘油三 酯濃度。 2 3 .如申請專利範圍第2 1項之營養組成物,其中 該日服劑量是含4至8錠魚油及3至5錠蒜、芸香苷及辣 椒素。 2 4 .如申請專利範圍第2 2項之營養組成物,其中 該日服劑量是含4至8錠魚油及3至5錠蒜 '芸香苷及及 辣椒素。 25.如申請專利範圍第23項或第24項之營養組 成物,其中該日服劑量含6錠魚油及4錠蒜、芳香苷與辣 椒素。 ----------裝------1T------^ ,(請先聞讀背面之注意事項r‘寫本頁) · 經濟部智^工""合作社印災 木紙浪足度適用令國國家樣辛(CNS ) A4说格(210 X 297公着’
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66108896A | 1996-06-10 | 1996-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW425285B true TW425285B (en) | 2001-03-11 |
Family
ID=24652162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085111211A TW425285B (en) | 1996-06-10 | 1996-09-13 | Fish oil and garlic nutritive supplement |
Country Status (2)
Country | Link |
---|---|
US (1) | US6326031B1 (zh) |
TW (1) | TW425285B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111479577A (zh) * | 2017-06-13 | 2020-07-31 | 夏滉 | 用于增强癌症放疗的组合物和方法 |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ511812A (en) * | 1998-11-25 | 2003-11-28 | Nutri Pharma As | Method of lowering lipid, triglyceride, total cholesterol and LDL-cholesterol serum levels and increasing the HDL/LDL cholesterol ratio thereby treating cardiovascular disease |
US20120237626A9 (en) * | 2000-12-05 | 2012-09-20 | Palu Afa Kehaati | Profiles of lipid proteins and inhibiting HMG-CoA reductase |
GB0411166D0 (en) * | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Treatment for asthma and arthritis |
WO2006009477A1 (en) * | 2004-07-22 | 2006-01-26 | University Of Otago | Anti-angiogenic compositions containing beeswax |
JP2011513401A (ja) * | 2008-03-03 | 2011-04-28 | ルナ イノベーションズ インコーポレイテッド | フラーレンを投与することにより動脈プラークの蓄積を抑制するための方法 |
US20110236476A1 (en) | 2008-09-02 | 2011-09-29 | Amarin Corporation Plc. | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
US8987328B2 (en) * | 2008-10-30 | 2015-03-24 | Trinity Laboratories, Inc. | Esters of capsaicinoids as dietary supplements |
KR20140007973A (ko) | 2009-02-10 | 2014-01-20 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US8846061B1 (en) * | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
US8343517B1 (en) * | 2011-03-08 | 2013-01-01 | Bezzek Mark S | Multivitamin-mineral longevity regimen |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
EP2866801A4 (en) | 2012-06-29 | 2016-02-10 | Amarin Pharmaceuticals Ie Ltd | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A SUBJECT SUBJECTED TO STATIN TREATMENT |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
CN105934161A (zh) | 2014-01-30 | 2016-09-07 | 奥米尼埃克蒂夫健康科技有限公司 | 含有油性的,辛辣的,有气味的物质的组合物和其制备方法 |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3520761A1 (de) | 1984-06-11 | 1985-12-12 | Ajinomoto Co., Inc., Tokio/Tokyo | Verwendung von vanillylamin oder vanillylamiden zur foerderung des fettstoffwechsels |
NO157302C (no) | 1985-12-19 | 1988-02-24 | Norsk Hydro As | Fremgangsmaate for fremstilling av et fiskeoljekonsentrat. |
US5578307A (en) | 1992-01-17 | 1996-11-26 | Alfatec-Pharma Gmbh | Shaped articles containing plant extract(s), in particular pellets, and their pharmaceutical or cosmetic use |
-
1996
- 1996-09-13 TW TW085111211A patent/TW425285B/zh not_active IP Right Cessation
-
1999
- 1999-12-13 US US09/461,303 patent/US6326031B1/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111479577A (zh) * | 2017-06-13 | 2020-07-31 | 夏滉 | 用于增强癌症放疗的组合物和方法 |
Also Published As
Publication number | Publication date |
---|---|
US6326031B1 (en) | 2001-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW425285B (en) | Fish oil and garlic nutritive supplement | |
Belay et al. | Current knowledge on potential health benefits of Spirulina | |
DE69931907T2 (de) | Zusammensetzungen aus hagebutten als anti-entzündliches natürliches arzneimittel zur erleichterung/verringerung von symptomen, die mit entzündungen und arthritis zusammenhängen | |
AU2009200897A1 (en) | Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides | |
Chalfoun-Mounayar et al. | Antioxidant and Weight Loss Effects of PomegranateMolasses | |
MXPA03001017A (es) | Uso de aceites esenciales para combatir la infeccion en el tracto gastrointestinal por organismos similares a helicobacter. | |
JP2008214191A (ja) | 肝中脂質蓄積抑制剤 | |
Benjamin et al. | Nutritional, phytochemical and sensory evaluation of “Mberiagworagwo” traditional food of Uruagunnewi people in Anambra State, Nigeria | |
KR100828069B1 (ko) | 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,지방간의 예방 또는 치료용 조성물 | |
Nkwocha et al. | Research Article Mineral and Vitamin Contents of Monodora myristica (African Nutmeg) Seeds from Nsukka, Enugu State, Nigeria | |
JP2006230225A (ja) | 血糖値上昇抑制作用を有する成分を含有する食品 | |
JP5305500B2 (ja) | リパーゼ阻害剤及びそれを含有する組成物 | |
JP2007045814A (ja) | コレステロール調節剤 | |
ELSadek | Chemical constituents of Eruca sativa and treatment activity against paracetamol inducing hepatic injury in experimental rats | |
JP2012131760A (ja) | 脂肪酸吸収抑制剤 | |
AU6282796A (en) | Fish oil and garlic nutritive composition | |
CN108095082A (zh) | 一种含有姜黄素的保健食品及其制备方法 | |
KR101524348B1 (ko) | 혈액순환장애의 예방 및 증상개선을 위한 오디 추출물 및 그 제조방법 | |
JP2005053818A (ja) | トリプシン阻害剤 | |
JP4997514B2 (ja) | 血圧上昇抑制剤 | |
Iba et al. | Potentials of ethnobotanicals and nutraceuticals in the management of sickle cell disease | |
Iba et al. | Potentials of ethnobotanicals and nutraceuticals in the management of sickle cell | |
García-Milla et al. | A Review of the Functional Characteristics and Applications of Aristotelia chilensis (Maqui Berry), in the Food Industry | |
A Ibrahim et al. | THE EFFECT OF BISCUITS FORTIFIED WITH PUMPKIN (CUCURBITA) SEEDS POWDER AND ITS OIL ON FATTY LIVER IN ALBINO RATS | |
CN111728978A (zh) | 罗汉果苷iie在制备抗氧化食品、保健品或药品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |